Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLC

NCT07377916 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: SHR-A1811

Sponsor

The First Affiliated Hospital of Guangzhou Medical University

Collaborators

[object Object]
[object Object]